Merz North America named David Dobrowski the vice president and head of North American Research and Development, effective immediately. He will be responsible for all medical, regulatory and product safety functions for Merz in North America and will lead the planning and execution of all clinical and pre-clinical development programs. He will additionally serve as the global lead on all Merz R&D activities relating to medical dermatology.
Dobrowski joined Merz in 2011 and most recently served as vice president, Regulatory Affairs and Product Safety. He brings more than 23 years of experience in the pharmaceutical and medical device space to his new role. Prior to joining Merz, Dobrowski held positions at Salix Pharmaceuticals, UCB Biosciences, Wyeth and Novartis, and his experience ranges across multiple specialties including aesthetics, dermatology, CNS, gastroenterology and opthalmics. Dobrowski is also a member of the Regulatory Affairs Professional Society (RAPS), Drug Information Association (DIA) and the North Carolina Regulatory Affairs Forum (NCRAF).
“Since joining Merz, David has established a track record of delivering consistently excellent results, as evidenced by the recent U.S. FDA approvals of Radiesse (+) with integral lidocaine and Radiesse for use in the hands,” said Bill Humphries, president and CEO of Merz North America. “We are confident that David’s leadership and professionalism will remain key to our ongoing success in North America, and that he and his team will continue to make critical contributions across all areas of our business.”
Merz also announced that Greg B. Bass—who previously held the role of vice president of Managed Markets—will assume responsibility for the Merz Dermatology Business Unit in the U.S. as vice president of Managed Markets and Medical Dermatology.
